The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Shaw, Executive Chairperson of Biocon & Biocon Biologics, said the pharma industry faces long 'lab-to-market' timelines, high ...

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research ...

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter, saying the Malaysia production facility still must undergo a pre-approval inspection to ...

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon ...

Biocon began the project in 2010, in part because of infrastructure issues in India that had not been addressed during an economic downturn. Mazumdar-Shaw said at the time that she took the ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Biocon Biologics is also separately likely to raise additional capital in the upcoming 12 months, Tambe told Mint earlier in June. The company’s current valuation is in the range of $5.4 billion.

Biocon's reported net profit for the quarter was ₹31 crore, compared to ₹660 crore in Q1FY25. Excluding one-time gains from a divestment in the corresponding quarter, its profit increased by 65%.

Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.

Biocon will target an initial public offering in India in late 2023. Pennsylvania-based Viatris will have the right to name on director to the Biocon board and will appoint its President, Rajiv ...